GLP-1 receptor agonists remain an important and rapidly changing area of pharmacy practice, with new therapies, expanding indications, and evolving safety considerations shaping patient care. This course reviews recent developments in GLP-1 therapy, including newly approved medications, emerging evidence related to nutrition and oral health, and practical considerations for patient counseling and long-term management. You will be better prepared to evaluate new evidence, counsel patients on the safe and effective use of GLP-1 therapies, and incorporate recent updates into clinical practice.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpact
GUEST
Jennifer D. Goldman, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice/Director of Cardiometabolic Services
Massachusetts College of Pharmacy-Boston, Well Life Medical
Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/
PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe recent developments in GLP-1 therapies, including newly approved medications.
2. Explain pharmacist-relevant considerations for counseling, safety monitoring, and long-term management of patients receiving GLP-1 therapies.
Jennifer Goldman is a member of the speakers bureau for Novo Nordisk, Amgen, Lilly, Xeris, CeQur, and Abbott Diabetes. All relevant financial relationships have been mitigated.
0.075 CEU/0.75 Hr
UAN: 0107-0000-26-323-H01-P
Initial release date: 9/14/2026
Expiration date: 9/14/2029
Additional CPE details can be found here.
